Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chloramphenicol + tetracycline + zinc oxide, commonly referred to as CTZ paste, is a multi-component antibiotic formulation used in Lesion Sterilization and Tissue Repair (LSTR) therapy for the management of primary teeth with pulp necrosis. The paste is composed of chloramphenicol, tetracycline, and zinc oxide, which are typically mixed with eugenol to serve as a vehicle. This combination provides broad-spectrum antimicrobial activity against the polymicrobial flora found in infected root canals, including both aerobic and anaerobic bacteria. By placing the paste in the pulp chamber, the therapy aims to achieve sterilization of the root canal system and promote periradicular tissue healing without the need for conventional mechanical instrumentation or obturation of the canals. This approach is particularly utilized in pediatric dentistry as a simplified, minimally invasive alternative to conventional pulpectomy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chloramphenicol + tetracycline + zinc oxide.